…
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Universal Biosensors develops and commercializes electrochemical biosensor platforms for point-of-care diagnostic tests, supplying disposable test strips and reader technologies to the medical diagnostics sector. Long-term growth may be supported by expanding the range of tests, licensing and partner agreements, and secular demand for decentralized testing, and investors may find the company attractive for its proprietary sensor technology and potential consumable-driven revenue model.
Key risks include execution and commercialization challenges, reliance on third-party partners and contracts, regulatory and reimbursement hurdles, competitive pressure from larger diagnostics firms, and potential funding or scale limitations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Income before tax | -14.24M | -10.24M | -29.91M | -10.51M | -7.64M |
| Net income | -14.24M | -6.74M | -26.85M | -10.30M | -7.67M |
| Selling general administrative | 16.01M | 14.45M | 11.08M | 5.61M | 5.88M |
| Gross profit | 4.00M | 4.28M | 2.14M | 2.11M | 0.62M |
| Reconciled depreciation | 0.80M | 1.35M | 2.79M | 2.57M | 2.43M |
| Ebit | -14.22M | -10.06M | -19.08M | -10.99M | -9.73M |
| Ebitda | -13.42M | -9.09M | -15.97M | -8.70M | -7.13M |
| Depreciation and amortization | 0.81M | 0.97M | 3.11M | 2.29M | 2.60M |
| Operating income | -16.97M | -16.68M | -19.08M | -10.99M | -9.73M |
| Other operating expenses | 23.25M | 23.31M | 23.60M | 16.77M | 12.93M |
| Interest expense | 0.10M | 0.18M | 0.02M | 0.12M | 0.15M |
| Tax provision | 0.00M | -3.05M | -3.05M | 0.00M | 0.00M |
| Interest income | 0.45M | 0.81M | 0.05M | 0.05M | 0.29M |
| Net interest income | 0.34M | 0.55M | 0.16M | -0.07M | 0.14M |
| Income tax expense | -2.20M | -3.50M | -3.05M | -0.21M | 0.03M |
| Total revenue | 6.28M | 6.63M | 4.52M | 5.78M | 3.20M |
| Total operating expenses | 20.97M | 20.97M | 21.22M | 13.09M | 10.36M |
| Cost of revenue | 2.28M | 2.35M | 2.39M | 3.67M | 2.58M |
| Total other income expense net | 2.73M | 6.44M | -10.83M | 0.48M | 2.09M |
| Net income from continuing ops | -14.24M | -17.64M | -26.85M | -10.51M | -7.64M |
| Net income applicable to common shares | -14.24M | -6.74M | -26.85M | -10.51M | -7.64M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Total assets | 25.84M | 30.12M | 46.15M | 44.50M | 56.38M |
| Intangible assets | - | - | 0.00M | 12.65M | 14.29M |
| Other current assets | 0.25M | 1.45M | 0.82M | 4.54M | 3.60M |
| Total liab | 8.47M | 10.61M | 20.05M | 16.89M | 18.40M |
| Total stockholder equity | 17.37M | 19.51M | 26.09M | 27.61M | 37.98M |
| Other current liab | - | 2.93M | 11.96M | 8.36M | 6.36M |
| Common stock | - | 0.02M | 0.02M | 0.02M | 0.02M |
| Capital stock | 0.03M | 0.02M | 0.02M | 0.02M | 0.02M |
| Retained earnings | -113.66M | -99.42M | -92.68M | -65.82M | -55.32M |
| Other liab | - | - | 2.97M | 5.80M | 5.81M |
| Other assets | - | - | 0.41M | 0.85M | 2.32M |
| Cash | 8.54M | 10.28M | 25.98M | 15.32M | 23.56M |
| Cash and equivalents | - | - | 25.98M | 15.32M | 23.56M |
| Total current liabilities | 4.66M | 5.95M | 13.09M | 9.40M | 8.96M |
| Current deferred revenue | - | 0.04M | 0.03M | 0.04M | 1.63M |
| Net debt | - | -5.30M | -21.15M | -13.06M | -19.40M |
| Short term debt | - | 1.75M | 0.83M | 0.57M | 0.52M |
| Short long term debt | 0.70M | 0.91M | 0.07M | 0.06M | - |
| Short long term debt total | - | 4.97M | 4.83M | 2.26M | 4.16M |
| Other stockholder equity | - | 119.24M | 119.04M | 93.74M | 93.57M |
| Property plant equipment | - | - | 9.06M | 6.15M | 8.38M |
| Total current assets | 18.47M | 22.00M | 36.67M | 24.85M | 31.40M |
| Net tangible assets | - | - | 26.09M | 14.96M | 23.69M |
| Net receivables | 0.96M | 5.90M | 5.71M | 0.48M | 0.07M |
| Long term debt | - | - | - | 0.00M | 0.04M |
| Inventory | 5.59M | 4.38M | 3.14M | 2.14M | 1.88M |
| Accounts payable | 0.36M | 1.24M | 0.27M | 0.44M | 0.45M |
| Accumulated other comprehensive income | - | -0.33M | -0.29M | -0.32M | -0.29M |
| Common stock total equity | - | - | - | - | 0.02M |
| Non currrent assets other | 0.41M | 0.09M | 0.41M | 0.85M | 2.32M |
| Non current assets total | 7.37M | 8.12M | 9.47M | 19.65M | 24.99M |
| Capital lease obligations | 3.31M | 4.06M | 4.76M | 2.19M | 4.12M |
| Long term debt total | - | - | 0.06M | 0.00M | 0.04M |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -0.41M | -1.60M | -1.57M | -0.66M | -0.37M |
| Change to liabilities | - | - | 0.16M | 0.35M | -2.55M |
| Total cashflows from investing activities | -0.41M | -1.47M | -1.57M | -0.66M | -0.37M |
| Net borrowings | -0.91M | -0.04M | -0.01M | 0.02M | 0.04M |
| Total cash from financing activities | 11.10M | -0.08M | 25.01M | 0.10M | 0.04M |
| Change to operating activities | - | - | -0.98M | -1.14M | -0.32M |
| Net income | -14.24M | -6.74M | -26.85M | -10.51M | -7.64M |
| Change in cash | -1.70M | -16.23M | 8.73M | -9.96M | -9.14M |
| Begin period cash flow | 10.60M | 26.50M | 18.10M | 28.06M | 37.19M |
| End period cash flow | 8.90M | 10.28M | 26.82M | 18.10M | 28.06M |
| Total cash from operating activities | -12.30M | -14.62M | -14.70M | -9.90M | -8.29M |
| Issuance of capital stock | 12.02M | 0.00M | 24.97M | - | - |
| Depreciation | 0.80M | 0.97M | 2.79M | 2.57M | 2.43M |
| Other cashflows from investing activities | - | - | - | 0.00M | 0.01M |
| Dividends paid | - | 0.03M | - | - | - |
| Change to inventory | -1.21M | -1.24M | -1.00M | -0.26M | -0.80M |
| Change to account receivables | 1.17M | -1.18M | -0.47M | -0.41M | 0.04M |
| Sale purchase of stock | 12.02M | -0.03M | 25.02M | 0.08M | 0.00M |
| Other cashflows from financing activities | -0.01M | -0.01M | 1.05M | -0.66M | -0.37M |
| Change to netincome | - | - | 11.65M | -0.50M | 0.54M |
| Capital expenditures | 0.41M | 1.47M | 1.57M | 0.66M | 0.39M |
| Change in working capital | 1.62M | -9.13M | -2.29M | -1.46M | -3.63M |
| Stock based compensation | 0.10M | 0.20M | 0.32M | 0.09M | 0.17M |
| Other non cash items | -0.59M | 0.09M | 11.33M | -0.59M | 0.37M |
| Free cash flow | -12.71M | -16.09M | -16.27M | -10.56M | -8.68M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COH Cochlear Ltd |
-0.54 0.36% |
150.83 | 67.28 | 29.41 | 4.22 | 5.69 | 4.23 | 29.91 |
| IMR Imricor Medical Systems Inc |
0.04 2.67% |
1.34 | - | - | 16380.35 | 17.45 | 4019.33 | -2.60 |
| AVR Anteris Technologies Global Corp |
-0.61 7.05% |
8.04 | - | - | 361.63 | 2.54 | 161.20 | -5.20 |
| AVH Avita Medical Inc |
-0.12 2.53% |
4.62 | - | 9.97 | 8.79 | 7.17 | 6.44 | 15.37 |
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also provides non-diagnostic laboratory services and coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.
1 Corporate Avenue, Rowville, VIC, Australia, 3178
61 3 9213 9000
76
| Name | Title | Year Born |
|---|---|---|
| Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin | Chief Exec. Officer | 1966 |
| Mr. Salesh Balak B.A., BA, C.A., CA | CFO & Company Sec. | 1969 |
| Mr. Nicholas Bliesner | Head of Operations | NA |
| Mr. Steven Burgess | Head of Sales & Marketing | NA |
| Mr. Luke Cossins B.Sc., M.B.A. | Head of R&D | NA |
| Ms. Ann Chew B.Com., CPA | Head of People Strategy & Culture | NA |
| Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin | Chief Executive Officer | 1966 |
| Mr. Salesh Balak B.A., BA, C.A., CA | CFO & Company Secretary | 1969 |
| Mr. Luke Cossins B.Sc., M.B.A. | Head of Research & Development | NA |
| Ms. Ann Chew B.Com., CPA, CIA | Head of People Strategy & Culture | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.